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Abstract: 
We propose a second method at an implementation level with cost and complexity reductions for monitoring HIV patients in 
resource-limited settings. The model is SMARThivPack, a “three tests” combo kit. Cost and complexity reductions of HIV 
patient monitoring technologies were described in a first model (at a technology development stage) proposed earlier. In 
developed countries, HIV patient clinical management programs comport three laboratory tests containing CD4 count, viral load 
measurement and pharmaco-resistance testing. In most developing countries only CD4 count is performed without the other two 
tests. Cost and complexity of required technologies are the major challenges to the developing world to meeting the “three tests” 
standard. SMARThivPack model achieves the “three tests” standard in the developing world by optimizing technology choice as 
to favour cross-use of equipments, thereby reducing equipment cost at the laboratory implementation level. Equipment cross use 
also reduces complexity by reducing training time, promoting specialization and substantiating experience in equipment use. The 
second level cost and complexity reductions model sets the grounds for a third level, global coordination cost and complexity 
reductions model.   
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Background: 
The acquired immuno-deficiency syndrome (AIDS) is a 
chronic disease requiring long term monitoring. Numerous 
studies established a link between AIDS and the Human 
Immudeficiency Virus (HIV). Chemotherapy-based treatment 
aiming to inhibit HIV replication exists. However, the virus 
evolves to develop resistance against AntiRetroVirals (ARVs) 
used in Chemotherapy, and continues replication in the 
presence of ARVs. HIV continued replication leads to 
increase plasma HIV RNA content (viral load) and decrease 
in the number of CD4 immune cells. Viral load and CD4 
number are markers for monitoring HIV replication and 
disease progression.  Pharmacoresistance testing is used to 
determine patterns of mutations conferring viral resistance to 
a given, generally three drugs regimens. Interpretation of the 
mutation patterns allows the choice of alternative drug 
regimens to further hinder virus replication. [1]  
 
CD4 counting, viral load measurement and, 
pharmacoresistance testing are three standard tests in the 
clinical management of HIV patients in the developed world. 
Standard technologies for performing the three tests are 
complex and expensive. Cost and complexity are the major 
challenges to the developing world to achieving the “three 
tests” standard. Required resources for equipment purchase 
and expertise for technology implementation, and tests 
execution are scarce in the developing world. Expert panels 
therefore recommended simpler and cheaper so called 
alternative technologies for the clinical management of HIV 
patients in the developing world. [2, 3, 4] Alternative 
technologies, for CD4 count, viral load measurement, and 
pharmacoresistance testing for the clinical management of 
HIV patients in the developing world, have been developed 
and evaluated. [5]   
 
Despite the availability of experts recommended alternative 
technologies for the three HIV patients monitoring laboratory 
tests, few nation level monitoring programs in the developing 
world, comport the three tests. CD4 count, as the solo 
laboratory test in the clinical management of HIV patients is 
the norm in most developing countries. [4]  
 
The World Health Organization (WHO) HIV patients 
treatment guidelines for the developing world, relied heavily 
on syndrome-based clinical management through careful 
symptoms monitoring, over sophisticated laboratory tests 
emphasized in developed countries. WHO emphasized 
simplicity and economy, and minimized substantial 
infrastructure improvement requirements. [6, 7]  
 
However, the forum for collaborative HIV research 
recommended laboratory monitoring of HIV patients in the 
developing world, to improve treatment outcomes and avoid 
drug resistance. [2]  
 
Both proponents and opponents of laboratory testing of HIV 
patients in the developing countries acknowledge the 
weaknesses of their approach. The committee that establishes 
the WHO guidelines acknowledges that setting science-based Bioinformation by Biomedical Informatics Publishing Group                   open access 
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different standards for poor patients in the developing world 
and rich patients in the developed world raised an ethical 
issue. Dr. Mark Wainberg, an HIV specialist at McGill 
University and former president of the International AIDS 
Society, comments on the WHO guidelines: “I was part of the 
committee that came up with the guidelines. I don't think they 
are perfect, but I doubt whether any similarly constituted 
group would improve significantly on the recommendations”. 
[7] Dr. Susan Fiscus, an HIV expert at the University of North 
Carolina at Chapel Hill and chair of the forum for 
collaborative HIV research acknowledges that developing 
countries economy and expertise level are serious challenges 
to implementing individual-centred sophisticated laboratory 
testing as performed in the developed world. [2]    
 
Biotech tropicana, Inc proposes an alternative HIV patient 
clinical management model that overcomes the weaknesses 
and reconcile the strengths of both the WHO approach and the 
Forum approach: SMARThivPack, a “three tests” combo kit, 
consisting of SMARThivCD4mos, SMARThivVLmos and , 
SMARThivDRmos . A detailed investigation of the available 
alternative technologies, specially designed for the developing 
world, showed that the “the three tests” laboratory testing 
standard is achievable in the developing word, by optimizing 
a combinatory technology choice as to favour equipment 
cross-use. SMARThivPack achieves the “three test” standard 
without substantial increase in cost while creating grounds for 
improving laboratory implementation and test execution 
quality. Cross use of equipments reduced equipment cost. 
Cross use of equipments also reduced training cost while 
substantiating experience in equipment use, thereby 
alleviating expertise barrier. Savings in equipments and 
training costs can be used to increase laboratory number 
without further investment.  
 
Description:  
The internet is a gold mine of information on HIV/AIDS basic 
research, HIV related technologies, and clinical data collected 
from HIV patients. [8] We used web-based data mining and 
detailed investigation of existing protocols on HIV laboratory 
monitoring technologies, to design an optimized laboratory 
model for monitoring HIV patients in the developing world. 
Our investigation focused on essential components of the 
indicated technologies and cost of implementation programs 
expressed as cost per test. The optimisation process aims to 
favour “user friendly” “automated” technologies that can 
carry as many tests as possible. Our model assumes HIV 
patient monitoring laboratory implementation within an 
existing health centre. Therefore, our model does not take into 
account essential components such as refrigerator, electrical 
supply and, computers which may be shared with other 
medical services. 
 
In the SMARThivPack model presented in table 1 (see 
supplementary material), equipment cost is reduced by 
choosing technologies that share essential equipments for the 
three tests. Elisa plate reader is the essential equipment for 
CD4 count and the viral load measurement. Viral load 
measurement capability is created without any further capital 
investment in essential equipment by choosing an elisa-based 
viral load measurement technology. The elisa plate reader can 
also be used for detection of HIV drug resistance conferring 
mutations in the OLA and ELMA technologies. Transferring 
the savings in viral load capability to establishing a PCR set 
up creates HIV drug resistance monitoring capability.  
 
Compared to the non optimized alternative technology model, 
optimization of equipment choice does not reduce the cost per 
three tests. However, SMARThivPack substantially reduces 
training cost. The elisa plate reader is an “alternative” 
“automated” technology that does not require long term 
training. Use of microscope in the “appropriate” dynabeads 
CD4 technology adds the requirement of a different skill, 
thereby increasing training cost. SMARThivPack requires two 
essential skills, PCR and elisa for execution of the three 
standard laboratory tests. Furthermore, the elisa plate reader 
can be used for qualitative hiv test.   
 
Compared to the standard reference technology model, 
SMARThivPack is far cheaper. Based on our model, thirty 
(30) SMARThivPack laboratories can be implemented from 
the total cost of one (1) standard reference laboratory.  
 
The $42/3tests using our SMARThivPack model, is within the 
cost range of classical diagnostic tests in monitoring other 
chronic diseases such as diabetes. In Benin Republic, a 
resource-limited country, cost of required tests in monitoring 
diabetes and other chronic diseases typically ranged between 
CFA 5000-10.000 ($USD 10-20) (Aboubakar YARI Biotech 
tropicana, Inc, personal investigation at Cotonou CHU, 
Benin). Diabetes is not health insurance covered and is paid 
for directly from patient’s income. [9]  HIV patient with 
average income in developing countries can similarly afford 
to pay for the $42 per three tests, particularly in light of the 
special subventions accorded to developing countries 
HIV/AIDS programs.  
 
The Biotech tropicana, Inc SMARThivCD4mos, 
SMARThivVLmos, and SMARThivDRmos, are dynamic 
structures of the Biotech tropicana, Inc SMARThivPack 
model. The CD4, VL, and DR technologies are chosen from 
the pool of available indicated technologies, based on existing 
equipments in a specific health centre, to overcome cost and 
complexity barriers. 
 
We demonstrate the feasibility of the individual-centred 
“three laboratory tests” in the clinical management of HIV 
patients in the developing world. Our SMARThivPack model 
overcomes cost and complexity barriers. Compared to 
programs implementing reference technologies, or non 
optimized alternative technologies, our model is far cheaper. 
Furthermore, by optimizing “technology choice” our model 
achieves substantial reduction of training period, while 
improving test execution quality. SMARThivPack is an ideal 
companion to generic AntiRetroViral drugs.  
 
It is now well accepted by all parties that alternative HIV 
patient monitoring strategies and technologies are the ultimate 
solution to the HIV/AIDS crisis in the developing world. 
However, approaches to applying these strategies and 
technologies toward achieving the objectives are an evolving 
area of sciences. Cost and complexity of the indicated 
alternative technologies are the major challenges to the 
developing world. Cost and complexity issues in the clinical 
management of HIV patients in the developing world were 
previously overcome with respect to AntiRetroViral drugs 
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conflicting approaches addressed the ARVs drugs 
accessibility issue; the pressure on pharmaceutical industry 
approach (“pressure approach”) [10], and the negotiation with 
pharmaceutical industry and developing countries government 
approach (“negotiation approach”). [11] The World Health 
Organization favours generic drugs, while the George W. 
BUSH PEPFAR program restricted funding of generic drugs 
that were not approved by the United States Food and drug 
Administration (FDA). The Clinton Foundation negotiation 
approach overcomes the weaknesses and reconciles the 
strengths of the WHO and BUSH approaches. The Clinton 
foundation succeeded in reducing cost and complexity of 
FDA-approved ARVs through a third level, careful 
coordination of drug development in the developed world and 
drug purchase by governments in the developing world. [11] 
Applying the Clinton Foundation strategy to laboratory 
monitoring, could promote the achievement of the individual-
centred “three-test” laboratory monitoring standard, in the 
developing world, by further reducing cost. Per unit cost of 
laboratory implementation will decrease, but the number of 
laboratories can be increased, thereby increasing the quantity 
of sales. Increase market will motivate private industry to 
further increase investment in research to improve alternative 
technologies for the developing world. Small and 
disorganised market so far limited industry interests. [4] 
Increase number of monitoring laboratories will increase 
treatment benefits. Morbidity and mortality will decrease. 
Decrease in morbidity will alleviate demands on already weak 
developing world public health systems, and put back HIV 
patients in the active developing world economy. Tangible 
results will be achieved. Results achievements will motivate 
further donations from the developed world public sector. 
Substantial proportion of the funds, invested in the fight 
against HIV/AIDS in the developing world, arose from the 
developed world public sector in the form of AID. [12] 
Biotech tropicana, Inc is in the process of investigating a third 
level, laboratory monitoring cost and complexity reduction 
strategy for the developing world. 
 
Expert panels recommended simpler and cheaper technologies 
for the clinical management of HIV patients in the developing 
world. [2, 3] Simpler technologies tend to demand substantial 
human input. Lab technicians in developing countries are 
getting infected, and the under staff developing world health 
systems put an extra burden on laboratory technicians who 
must also perform testing on other endemic diseases such as 
malaria and tuberculosis. There arose the “technology type” 
question. The so called “Appropriate Technologies” for the 
developing world tends to combine “low tech” with 
“simplicity” and “low cost”. The drawbacks of these 
technologies are that they tend to demand substantial human 
input and are therefore error-prone. “Alternative 
technologies” as defined by Biotech tropicana, Inc are “user-
friendly”, “cutting-edge techs” that combine “automation” 
with “simplicity” and “low cost”, thereby reducing human 
input. Biotech tropicana, Inc is investigating the issues of 
“technology type” and “technology choice” for the 
developing world.  
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Supplementary material 
 
  Standard reference technology  Non optimized alternative 
technology 
SMARThivPack
a 
 
CD4  Standard Flow 
 
Dynabeads (fluorescent 
microscope) 
Capcellia (elisa plate 
reader) 
VL  Cobas Amplicor HIV-1 Monitor 
Test v1.5 
( Cobas  system) 
Exavir (gel filtration system, 
elisa plate reader, elisa plate 
washer
b) 
P24 (elisa plate reader
c) 
Essential 
Technology 
(Equipments) 
DR  ViroSeq (Automatic Sequencer, 
Thermal Cycler, gel 
electrophoresis system) 
OLA
d (pcr set up, elisa plate 
reader, elisa plate washer) 
ELMA
d (pcr set up, 
elisa plate reader,) 
CD4  $USD 60.000
e  $ USD 6000  $ USD 3.000 
VL  $ 90.000
f $  7000
g  $ USD 0
 h 
DR  $ USD 100.000
 i $  5000
j  $ USD 5000 
Equipment 
Cost 
Total  $ USD 250.000  $ USD 18.000  $ USD 8000 
CD4  $ USD 26/test  $ USD 4.5/test  $ USD 17/test
k 
VL  $USD 26/test
 l  $ USD 15/test  $ USD 12.5/test
m 
DR  $USD 350
n  $ USD 12.5/test
m  $ USD  12.5/test
m 
Implementation 
Cost (cost/test) 
Total  $ USD 402/ 3 tests  $ USD 32/ 3 tests  $ USD 42/ 3 tests 
Table 1: Comparison of essential equipments choice in a standard HIV patient monitoring laboratory with SMARThivPAck 
model HIV patient monitoring laboratory in developing countries is given. (a) The SMARThivPack model presented in this table 
is an illustration of the SMARThivPack concept and should not be construed as a universal developing countries HIV patients 
monitoring laboratory model. The SMARThivPack model should be adjusted to specific laboratory setting, particularly in light of 
existing equipments and cost of consumables. (b) A plate washer is a recommended not essential equipment in performing an 
elisa test. Most elisa kits come with a manual washing protocol. (c) The elisa plate can be used for CD4, VL, and DR assays. (d) 
Details on OLA and ELMA technologies are available at, [13] and [14] respectively. (e) Unless otherwise specified all costs are 
averaged from http://www.hivforum.org/publications/QAQC.pdf  appendixes B and C. Cost is averaged from 
http://mednet2.who.int/sourcesprices/sp_1b.pdf. (f) From web survey of 5 manufacturer catalogues, cost of elisa plate 
reader/washer is averaged to $USD 3000 each, and cost of the gel filtration system is averaged to $1000. (g) See c). (h) Cost is 
estimated based on specific requirements of DNA sequencing facility and cost of genetic analyzers. (i) From web survey of 5 
manufacturer catalogues, cost of the pcr set up is average to $USD 5000. (j) Cost as applied in South Africa. 
http://www.aidsinfonyc.org/fiar/croi11-app3.html. (k) Cost is averaged from same reference as in f); (l) Cost is estimated from 
same reference as in f) based on similarity of essential steps (pcr amplification and elisa detection). (m) Cost range is $USD 200-
500 from [15] 
 